Tiziana Life Sciences Ltd (TLSA)
$0.7349
Rating:
Recommendation:
-
| Symbol | TLSA |
|---|---|
| Price | $0.7349 |
| Beta | 0.000 |
| Volume Avg. | 0.15M |
| Market Cap | 73.923M |
| Shares () | - |
| 52 Week Range | 0.5-1.39 |
| 1y Target Est | - |
| DCF Unlevered | TLSA DCF -> | |
|---|---|---|
| DCF Levered | TLSA LDCF -> | |
| ROE | -5.17% | Neutral |
| ROA | -5.60% | Neutral |
| Operating Margin | - | |
| Debt / Equity | 17.68% | Neutral |
| P/E | -4.90 | Strong Sell |
| P/B | 1.75 | Strong Buy |
Latest TLSA news
About
Download (Excel)Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.